Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 6:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 237 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ABP 501 Clear all
Terminated Phase 4 Interventional Results available

Effects of Abatacept on Myocarditis in Rheumatoid Arthritis

NCT03619876
View directory record Official record
Conditions
Rheumatoid Arthritis, Myocardial Inflammation
Interventions
Abatacept, Adalimumab
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2023 · Synced Sep 4, 2026, 6:16 AM EDT
Completed Phase 4 Interventional Results available

IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA

NCT02451748
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Lab Work, Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg), Certolizumab pegol (CDP870, tradename Cimzia), Hydroxychloroquine, Sulfasalazine, Medrol, Prednisone, Triamcinolone, Naproxen, Leflunomide, Methotrexate, humira
Other · Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Sep 4, 2026, 6:16 AM EDT
Completed Phase 3 Interventional Results available

BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis

NCT02137226
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
BI 695501, US-licensed Humira®
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
645 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
63
States / cities
Anniston, Alabama • Birmingham, Alabama • Glendale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Sep 4, 2026, 6:16 AM EDT
Completed Phase 3 Interventional Results available

A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis

NCT04230213
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
PF-06410293, adalimumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Bowling Green, Kentucky • Duncansville, Pennsylvania • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Sep 4, 2026, 6:16 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis

NCT01970475
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
ABP 501, Adalimumab
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Victorville, California • Jupiter, Florida • Sandy Springs, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2016 · Synced Sep 4, 2026, 6:16 AM EDT
Completed No phase listed Observational

Cytokines and Genes in Therapeutic Response in Crohn's Disease

NCT03266471
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Baseline blood sample, Baseline intestinal biopsies, Crohn's disease activity index (CDAI), Post treatment blood sample, Post treatment intestinal biopsies, Baseline stool sample, Post treatment stool sample
Diagnostic Test · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Sep 4, 2026, 6:16 AM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy

NCT04115748
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Filgotinib, Adalimumab, Placebo to match filgotinib, Placebo to match adalimumab
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
24
States / cities
Covina, California • Brandon, Florida • DeBary, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated May 15, 2022 · Synced Sep 4, 2026, 6:16 AM EDT
Terminated Not applicable Interventional

Proactive Therapeutic Drug Monitoring Based Adalimumab Therapy Optimization in Patients With Rheumatoid Arthritis

NCT05460390
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Therapeutic drug monitoring (TDM)
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Sep 4, 2026, 6:16 AM EDT
Recruiting Phase 2 Interventional

Pragmatic, Open-Label Study to Pilot Evaluation for Clinical Trials in Relapsing Polychondritis

NCT06941376
View directory record Official record
Conditions
Relapsing Polychondritis
Interventions
Methotrexate (MTX), Azathioprine (AZA), Adalimumab, Infliximab, Tocilizumab
Drug · Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 4, 2026, 6:16 AM EDT
Withdrawn Phase 2 Interventional

Efficacy Study of Humira in the Treatment of Cutaneous Sarcoidosis

NCT00731757
View directory record Official record
Conditions
Sarcoidosis, Cutaneous Sarcoidosis
Interventions
Humira
Drug
Lead sponsor
Wright State University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Sep 4, 2026, 6:16 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis

NCT02114931
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
ABP 501
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 81 Years
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
29
States / cities
Huntsville, Alabama • Peoria, Arizona • Scottsdale, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2017 · Synced Sep 4, 2026, 6:16 AM EDT
Completed Phase 4 Interventional Results available

Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis

NCT02557100
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, Adalimumab, Methotrexate
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
21
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Sep 4, 2026, 6:16 AM EDT
Recruiting Phase 4 Interventional

Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis

NCT03827876
View directory record Official record
Conditions
Psoriasis
Interventions
Enstilar 0.005%-0.064% Topical Foam
Drug
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 3, 2019 · Synced Sep 4, 2026, 6:16 AM EDT
Completed Phase 4 Interventional

Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint Disease

NCT01893996
View directory record Official record
Conditions
Rheumatoid Arthritis, Cardiovascular Disease
Interventions
Adalimumab, Placebo
Drug
Lead sponsor
Jonathan Graf
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Sep 4, 2026, 6:16 AM EDT
Active, not recruiting Phase 1 Interventional

Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery

NCT02160015
View directory record Official record
Conditions
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Electrocardiogram, Ibrutinib, Lenalidomide, Magnetic Resonance Imaging, Rituximab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 4, 2026, 6:16 AM EDT
Completed Phase 2 Interventional Results available

The Usability and Injection Time of the Physiolis Syringe and Autoinjector in Rheumatoid Arthritis Patients

NCT01163617
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Adalimumab delivered in current syringe, Adalimumab delivered in Physiolis syringe, Adalimumab delivered in current autoinjector, Adalimumab delivered in Physiolis autoinjector
Device
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
10
States / cities
Victorville, California • Tampa, Florida • Passaic, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Sep 4, 2026, 6:16 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease

NCT00325078
View directory record Official record
Conditions
Chronic Granulomatous Disease, Crohn'S-like IBD, Inflammatory Bowel Disease (IBD)
Interventions
Infliximab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
10 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 28, 2015 · Synced Sep 4, 2026, 6:16 AM EDT
Completed Phase 2 Interventional Results available

Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma

NCT03019640
View directory record Official record
Conditions
Mantle Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Indolent Adult Non-Hodgkin Lymphoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cord Blood-derived Expanded Allogeneic Natural Killer Cells, Cytarabine, Etoposide, Filgrastim, Lenalidomide, Melphalan, Rituximab
Procedure · Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Sep 4, 2026, 6:16 AM EDT
Completed Phase 3 Interventional Results available

Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)

NCT00048542
View directory record Official record
Conditions
Arthritis, Juvenile Idiopathic
Interventions
Double-Blind Adalimumab/Placebo + MTX, Double-Blind Adalimumab/Placebo, OLE BSA Adalimumab +/- MTX, OLE FD Adalimumab +/- MTX
Biological · Drug
Lead sponsor
Abbott
Industry
Eligibility
4 Years to 17 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2011 · Synced Sep 4, 2026, 6:16 AM EDT
Not yet recruiting Phase 4 Interventional

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

NCT07352566
View directory record Official record
Conditions
Psoriasis, Atopic Dermatitis
Interventions
In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil, Calcipotriene, Tapinarof, Crisaborole, Tacrolimus, Adalimumab, Etanercept, Certolizumab, Infliximab, Secukinumab, Ixekizumab, Apremilast, Risankizumab, Ustekinumab, Hydroxychloroquine, Methotrexate, Mycophenolate, Azathioprine, Chloroquine, Cyclosporine, Tofacitinib, Deucravacitinib, Dupilumab, Tralokinumab, Guselkumab, Tildrakizumab, Baractinib, Abrocitinib, Upadacitinib, Lebrikizumab, Nemolizumab, Ruxolitinib, Bimekizumab, Roflumilast
Device · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 4, 2026, 6:16 AM EDT
Active, not recruiting Phase 2 Interventional

Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma

NCT04404088
View directory record Official record
Conditions
Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma, Grade 3a Follicular Lymphoma
Interventions
Acalabrutinib, Lenalidomide, Rituximab
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 4, 2026, 6:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects (REFLECTIONS B538-07))

NCT02237729
View directory record Official record
Conditions
Healthy Subjects
Interventions
PF-06410293, Adalimumab-US, Adalimumab-EU
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 45 Years
Enrollment
362 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
8
States / cities
Coral Gables, Florida • Jacksonville, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2015 · Synced Sep 4, 2026, 6:16 AM EDT
Completed Phase 4 Interventional Results available

A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

NCT02814175
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
methotrexate (MTX), adalimumab (ADA)
Drug · Biological
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
12
States / cities
Sun City, Arizona • Miami, Florida • Vernon Hills, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Sep 4, 2026, 6:16 AM EDT
Not yet recruiting Phase 4 Interventional

Adalimumab Dose Adjustment for Pediatric Uveitis Treatment Trial

NCT07699107
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis Associated Uveitis, Uveitis, Anterior
Interventions
Adalimumab/Biosimilar
Biological
Lead sponsor
Nisha Acharya
Other
Eligibility
2 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
9
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 4, 2026, 6:16 AM EDT